Home › Depression › New York › Staten Island
Depression clinical trials in Staten Island, NY
4 studies for Depression are looking for participants at sites in and around Staten Island (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RecruitingPhase 2
- Seaport Investigator Site, Staten Island
E-Mindfulness Approaches for Living After Breast Cancer
RecruitingPhase 3
- Bayshore Community Hospital, Holmdel · 15 mi away
- Riverview Medical Center/Booker Cancer Center, Red Bank · 15 mi away
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
RecruitingPhase 3
- Richmond Behavioral Associates, Staten Island
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RecruitingPhase 4
- Clinical Research Site, Staten Island
About Depression
Depression is a serious medical illness. It affects almost 7 percent of U.S. adults. It causes feelings of sadness, hopelessness, and frustration that do not go away. Learn about treatments.
More about Depression on MedlinePlus
Depression trials in other cities
- Boston, MA51 studies
- New York City, NY45 studies
- Philadelphia, PA25 studies
- Atlanta, GA23 studies
- Chicago, IL23 studies
- Pittsburgh, PA22 studies
- San Diego, CA21 studies
- Charleston, SC19 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Orlando, FL17 studies
- San Francisco, CA15 studies
Other studies in Staten Island
- Breast Cancer40 studies
- Non-Small Cell Lung Cancer19 studies
- Prostate Cancer16 studies
- Acute Myeloid Leukemia14 studies
- Multiple Myeloma13 studies
- Endometrial Cancer12 studies
- Lung Cancer12 studies
- Bladder Cancer11 studies
- Cancer (all types)11 studies
- Metastatic Cancer10 studies
- Ovarian Cancer9 studies
- Head and Neck Squamous Cell Carcinoma9 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.